Thrombosis

Report Year

Trial Code

Trial Title

Clinicaltrials.gov

EudraCTno.

Source

2015

IN 0901 INT

Efficacy and safety of long-term (6 months) innohep® treatment versus anticoagulation with a vitamin K antagonist (warfarin) for the treatment of acute venous thromboembolism in cancer patients

NCT01130025

2009-018141-20

Summary

Report

Active Substance

tinzaparin

LEO Pharma Product

innohep®

Formulation

injection solution

Trial Phase

3

Population

adults

2010

IN 0103 CA

Tinzaparin perioperative bridging study

N/A

N/A

Summary

Report

Active Substance

tinzaparin

LEO Pharma Product

innohep®

Formulation

injection solution

Trial Phase

2

Population

adults

2009

IN 0201 ES

Single doses of tinzaparin in the prevention og coagulation in haemodialysis lasting more than 4 hours

N/A

N/A

Summary

Report

Active Substance

tinzaparin

LEO Pharma Product

innohep®

Formulation

injection solution

Trial Phase

4

Population

adults

2009

IN 0401 INT

Safety profile of innohep® versus subcutaneous unfractionated heparin in eldery patients with impaired renal function treated for acute deep vein thrombosis

NCT00277394

2005-002270-29

Summary

Report

Active Substance

tinzaparin & heparin

LEO Pharma Product

innohep® & Heparin LEO

Formulation

injection solution

Trial Phase

4

Population

Elderly

2006

IN 0102 FR

innohep® 4,500 IU and Lovenox® 40 mg a pharmacodynamic study at repeated dose

N/A

N/A

Summary

Report

Active Substance

tinzaparin

LEO Pharma Product

innohep®

Formulation

injection solution

Trial Phase

3

Population

Elderly

2002

IN 9301 DK

Efficacy, safety and acceptability of innohep® (tinzaparin) 3500 anti-Xa IU as a prophylactic in thrombosis in patients with immobilised lower limb

N/A

N/A

Summary

Report

Active Substance

tinzaparin

LEO Pharma Product

innohep®

Formulation

injection solution

Trial Phase

3

Population

Adults

2001

IN 9603 INT

innohep® in pregnancy

N/A

N/A

Summary

Report

Active Substance

tinzaparin

LEO Pharma Product

innohep®

Formulation

injection solution

Trial Phase

3

Population

Adults

2001

IN 9702 INT

Prolonged innohep® thromboprophylaxis following abdominal and/or pelvic cancer surgery

N/A

N/A

Report

Active Substance

Tinzaparin

LEO Pharma Product

innohep®

Formulation

Injection solution

Trial Phase

3

Population

Adults

1999

IN 9502 FR

Tinzaparin in the treatment of pulmonary embolism

N/A

N/A

Summary

Report

Active Substance

tinzaparin & heparin

LEO Pharma Product

innohep® & Heparin LEO

Formulation

injection solution

Trial Phase

3

Population

Adults

1999

TI93AB FR

Efficacy and tolerance study of tinzaparin in the prevention of post-operative venous thromboembolic complications after elective hip surgery

N/A

N/A

Summary

Report

Active Substance

tinzaparin

LEO Pharma Product

innohep®

Formulation

injection solution

Trial Phase

3

Population

Adults

1995

TI93AA FR

Efficacy and tolerance study of tinzaparin in the prevention of post-operative venous thromboembolic complications after elective hip surgery

N/A

N/A

Summary

Report in French  Description: http://leo-pharma.com/Files/Billeder/flag_france_clinical_trials.png

Active Substance

tinzaparin

LEO Pharma Product

innohep®

Formulation

injection solution

Trial Phase

3

Population

Adults

We use cookies on this website

The cookies help us gain a better understanding of how you use our website; display applications and functionalities, to optimise your website experience, to assign a unique identification number to you, and to help you remember your user ID and password when you return to the website. We also use cookies to generate statistical information.

By continuing to browse our website, you are agreeing to our use of cookies

If you want to know more about our cookie policy and how to avoid and delete cookies click here.